Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT

Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and
application of three-dimensional Spherical Nucleic Acid (SNA™)
constructs as gene regulatory and immunotherapeutic agents, announced
today that Dr. David Giljohann, Chief Executive Officer of Exicure, will
present at the JMP Securities Life Sciences Conference on Thursday, June
21st, 2018 at 11:00 a.m. EDT in New York City at The St. Regis New York.

A live webcast of the presentation will be available on the Events
& Presentations section of Exicure’s website, where it will also
be archived and available for replay following the presentation for 30

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new
class of immunomodulatory and gene regulating drugs against validated
targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid
(SNA™) architecture unlocks the potential of therapeutic
oligonucleotides in a wide range of cells and tissues. Exicure’s lead
programs address oncology, inflammatory diseases and genetic disorders.
Exicure is based outside of Chicago, IL. For more information, please
visit www.exicuretx.com.

Forward Looking Statements

This press release contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange Act
of 1934, as amended, and Section 27A of the United States Securities Act
of 1933, as amended) concerning the Company, the Company’s technology,
potential therapies, pre-clinical results, and other matters.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “would,”
“expect,” “plan,” “believe,” “intend,” “look forward,” and other similar
expressions among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors, including,
without limitation: that Exicure’s pre-clinical programs do not advance
into the clinic or result in approved products on a timely or cost
effective basis or at all; regulatory developments; and the ability of
Exicure to obtain sufficient funding for its programs and to protect its
intellectual property rights. Exicure’s pipeline programs are in various
stages of pre-clinical and clinical development, and the process by
which such pre-clinical or clinical therapeutic candidates could
potentially lead to an approved therapeutic is long and subject to
significant risks and uncertainties. Risks facing the Company and its
programs are set forth in the Company’s filings with the SEC. Except as
required by applicable law, the Company undertakes no obligation to
revise or update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005193/en/